Nesvacumab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) MAB data |
Entranced98 (talk | contribs) Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound" |
||
| (8 intermediate revisions by 7 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Monoclonal antibody}} |
|||
{{Drugbox |
{{Drugbox |
||
| type = mab |
| type = mab |
||
| image = |
| image = |
||
| alt = |
| alt = |
||
| mab_type = mab |
| mab_type = mab |
||
| source = u |
| source = u |
||
| target = [[Angiopoietin 2]] |
| target = [[Angiopoietin 2]] |
||
| tradename = |
| tradename = |
||
| Drugs.com = |
| Drugs.com = |
||
| MedlinePlus = |
| MedlinePlus = |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
| pregnancy_US = |
| pregnancy_US = |
||
| pregnancy_category= |
| pregnancy_category= |
||
| legal_AU = |
| legal_AU = |
||
| legal_CA = |
| legal_CA = |
||
| legal_UK = |
| legal_UK = |
||
| legal_US = |
| legal_US = |
||
| legal_status = |
| legal_status = Investigational |
||
| routes_of_administration = |
| routes_of_administration = |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| CAS_number = 1296818-77-3 |
| CAS_number = 1296818-77-3 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = WX8293WGLC |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| IUPHAR_ligand = 8457 |
| IUPHAR_ligand = 8457 |
||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID = none |
| ChemSpiderID = none |
||
| KEGG = D10395 |
| KEGG = D10395 |
||
| C=6440 | H=9966 | N=1722 | O=2008 | S=38 |
| C=6440 | H=9966 | N=1722 | O=2008 | S=38 |
||
| molecular_weight = 144.9 kg/mol |
|||
}} |
}} |
||
'''Nesvacumab''' is |
'''Nesvacumab''' is an experimental [[monoclonal antibody]] originally designed for the treatment of cancer. It targets the protein [[angiopoietin 2]].<ref>[http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab], ''[[American Medical Association]]''.</ref><ref name="Hussain_2019">{{cite journal | vauthors = Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA | title = Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease | journal = Expert Opinion on Investigational Drugs | volume = 28 | issue = 10 | pages = 861–869 | date = October 2019 | pmid = 31513439 | doi = 10.1080/13543784.2019.1667333 }}</ref> {{as of|2017|5}}, it is in [[Phase II clinical trial]]s for the treatment of [[diabetic macular edema]].<ref>{{clinicalTrialsGov|NCT02713204|Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)}}</ref><ref>{{clinicalTrialsGov|NCT02712008|Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)}}</ref> |
||
This drug |
This drug is being developed by [[Regeneron Pharmaceuticals]].{{cn|date=February 2023}} |
||
== References == |
== References == |
||
<references/> |
<references /> |
||
{{monoclonals for tumors}} |
{{monoclonals for tumors}} |
||
| Line 45: | Line 47: | ||
{{Growth factor receptor modulators}} |
{{Growth factor receptor modulators}} |
||
| ⚫ | |||
[[Category:Monoclonal antibodies]] |
[[Category:Monoclonal antibodies]] |
||
[[Category:Experimental cancer drugs]] |
[[Category:Experimental cancer drugs]] |
||
| ⚫ | |||
Latest revision as of 15:27, 19 May 2023
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Angiopoietin 2 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6440H9966N1722O2008S38 |
| Molar mass | 144860.89 g·mol−1 |
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1][2] As of May 2017[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.[3][4]
This drug is being developed by Regeneron Pharmaceuticals.[citation needed]
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
- ^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA (October 2019). "Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease". Expert Opinion on Investigational Drugs. 28 (10): 861–869. doi:10.1080/13543784.2019.1667333. PMID 31513439.
- ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
- ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |